Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicriviroc and MK-2048 IVR for HIV prevention
NCT02419456Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vicriviroc and MK-2048 in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2015; status: completed.
02
Drugs
vicrivirocMK-2048
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02419456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419456.